• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by BioVie Inc.

    12/12/22 8:00:14 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIVI alert in real time by email
    RW 1 bivi-20221212_rw.htm RW

    BioVie Inc.

    680 W Nye Lane
    Suite 204

    Carson City, NV 89703

     

    VIA EDGAR

     

    December 12, 2022

     

    U.S. Securities & Exchange Commission

    Division of Corporation Finance

    Office of Energy & Transportation

    100 F Street, NE

    Washington, D.C. 20549

    Attn: Lauren Hamill

     

      Re:

    BioVie Inc. (CIK 0001580149)

    Registration Statement on Form S-1

     

    Dear Ms. Hamill:

     

    Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), BioVie Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of its Registration Statement on Form S-1 (File No. 333-268313) together with all exhibits thereto (the “Registration Statement”), effective as of the date hereof or at the earliest practicable date hereafter. The Registration Statement was originally filed by the Company on November 10, 2022.

     

    The Company has determined to withdraw the Registration Statement and not pursue the public offering at this time. The Registration Statement has not been declared effective by the Commission and the Company confirms that no securities have been sold pursuant to the Registration Statement. Therefore, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477.

     

    The Company requests that, in accordance with Rule 457(p) under the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.

     

    If you have questions regarding this letter, please feel free to contact to our counsel, Michael S. Lee, at [email protected] or by telephone at (212) 549-0358.

     

     

     

     

      Sincerely,  
         
      /s/ Joanne Wendy Kim  
      Joanne Wendy Kim  
      Chief Financial Officer  
      BioVie Inc.  

     

    cc: Michael S. Lee, Reed Smith LLP

    Mark G. Pedretti, Reed Smith LLP

    Get the next $BIVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIVI

    DatePrice TargetRatingAnalyst
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    More analyst ratings

    $BIVI
    SEC Filings

    See more
    • SEC Form PRE 14A filed by BioVie Inc.

      PRE 14A - BIOVIE INC. (0001580149) (Filer)

      5/8/25 5:20:30 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14C filed by BioVie Inc.

      PRE 14C - BIOVIE INC. (0001580149) (Filer)

      5/7/25 5:20:08 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Inc. filed SEC Form 8-K: Leadership Update

      8-K - BIOVIE INC. (0001580149) (Filer)

      3/28/25 5:00:27 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Do Cuong V bought 10,000 shares (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      3/6/24 5:12:41 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Do Cuong V bought $17,800 worth of shares (10,000 units at $1.78), increasing direct ownership by 17% to 68,759 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      12/1/23 6:26:32 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

      CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City. Details for the presentation are as follows: Title: Assessment of Bezisterim (NE3107) in Pati

      5/7/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

      The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

      5/5/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled

      SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson's disease treatment to incorporate a decentralized approach option to allow for remote participation Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson's Foundation Topline data anticipated in Late 2025 or Early 2026 CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company devel

      4/16/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Leadership Updates

    Live Leadership Updates

    See more
    • BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

      The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

      5/5/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

      CARSON CITY, Nev., June 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of a long COVID Advisory Board that will provide the Company with strategic guidance on the design and execution of a Phase 2b trial in patients with long COVID, with funding from the U.S. Department of Defense. Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or

      6/4/24 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Announces the Appointment of a New Chief Medical Officer

      RENO, Nev., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurodegenerative disease - announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company's new Chief Medical Officer. In this role Dr. Palumbo will oversee the Company's clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of ERK and NFkB (e.g. TNF transcription) expected to modulate neuroinflammation and insulin resistance, while still facilitating the homeostatic function inherent to their mechanisms (

      11/1/21 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioVie Inc.

      SC 13G - BIOVIE INC. (0001580149) (Subject)

      10/25/24 4:01:25 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioVie Inc.

      SC 13D/A - BIOVIE INC. (0001580149) (Subject)

      6/25/24 7:47:33 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by BioVie Inc. (Amendment)

      SC 13D/A - BIOVIE INC. (0001580149) (Subject)

      3/10/23 5:15:43 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rogich Sigmund was granted 32,700 shares, increasing direct ownership by 774% to 36,926 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:26:37 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berman Richard J was granted 34,200 shares, increasing direct ownership by 531% to 40,643 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:24:53 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sherman Michael Edward

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:21:05 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on BioVie Inc. with a new price target

      Cantor Fitzgerald initiated coverage of BioVie Inc. with a rating of Overweight and set a new price target of $7.00

      7/22/22 7:51:28 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities reiterated coverage on BioVie with a new price target

      B. Riley Securities reiterated coverage of BioVie with a rating of Buy and set a new price target of $27.00 from $50.00 previously

      11/30/21 8:23:48 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Financials

    Live finance-specific insights

    See more
    • BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

      CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City. Details for the presentation are as follows: Title: Assessment of Bezisterim (NE3107) in Pati

      5/7/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled

      SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson's disease treatment to incorporate a decentralized approach option to allow for remote participation Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson's Foundation Topline data anticipated in Late 2025 or Early 2026 CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company devel

      4/16/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

      CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st & 22nd 2024, in Barcelona Spain. The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter t

      11/20/24 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care